SIGNIFICANCE OF ALDOSTERONE-SYNTHESIS GENE POLYMORPHISM IN THE DEVELOPMENT OF FIBROSIS PROCESSES IN CARDIORENAL SYNDROME DEVELOPED ON THE BASIS OF CHRONIC HEART FAILURE
Abstract
In this article, the importance of aldosterone-synthesis gene polymorphism in the development of fibrosis processes in cardiorenal syndrome developed on the basis of chronic heart failure is studied. The obtained results showed that the C344T polymorphism of the CYP11B2 gene in chronic heart failure is consistent with the TT genotype and the occurrence of cardiorenal syndrome as a result of the T allele, and the TT genotype is consistent with the severe course of the disease. Based on different hemodynamic types of CHF, in patients with advanced cardiorenal syndrome, CYP11B2 gene C344T polymorphism carriers of the SS genotype had lower serum aldoterone levels than patients with ST and TT genotypes.
Keywords
chronic heart failure, cardiorenal syndrome, aldosteroneHow to Cite
References
Brazhnik V.A., Zateishchikov D.A., Sidorenko B.A. Hereditary factors and left ventricular hypertrophy // Cardiology. - 2003. - No. 1. - P. 78-88.
Kutyrina I.M. Nephroprotective properties of angiotensin II synthesis blockers: the effect of renitec on proteinuria. Heart failure. 2000; 1(3): 92-93.
Lapshina L.A., Kravchun P.G., Lepeeva E.A. The role of aldosterone in the process of myocardial remodeling // Kharkov State Medical University - 2005.
Medvedeva E.A., Shilyaeva N.V. Cardiorenal syndrome in chronic heart failure: pathogenesis, diagnosis, prognosis and possibilities of therapy. Russian journal of cardiology. 2017; 141(1): 136-141.
Storozhakov G.I., Gendlin G.E., Reznik E.V., If the heart hurts, the kidneys suffer: cardiorenal syndrome in chronic heart failure. Medical business. 2009; 1:27-36.
Bleeker M.W., De Groot P.C., Pawelczyk J.A. et al. Effects of 18 days of bed rest on leg and arm venous properties. J Appl Physiol. 2004; 96 (3): 840-7.
Boerrigter G., Lapp H., Burnett J.C., Modulation of cGMP in heart failure: a new therapeutic paradigm. Handb Exp Pharmacol. 2009; 191: 485-506.
Brilla C.G., Zhou G., Weber K.T. Aldosterone-mediated stimulation of collagen synthesis in cultured cardiac fibroblasts // J. Hypertension. – 1992. – Vol.10. – Р. 7.
Delcayre C., Swynghedauw B. Molecular mechanisms of myocardial remodelling. The role of aldosterone // J. Mol. Cell. Cardiology. – 2002. – Vol. 34. – P. 1577-1584.
Delles C., Erdmann J., Jacobi J. et al. Aldosterone synthase (CYP11B2)-344C/T polymorphism is associated with left ventricular structure in human arterial hypertension // J. Amer. Coll. Cardiology. – 2001. – Vol. 37. – P. 878-884.
Junick P.C., Lewis S.Y., Brody M.Y. Role of central mineralocorticoid binding sites in development of hypertension // Amer. J. Physiology. – 1990. – Vol. 259. – P. 1025-1034.
Kupari M., Hauten A., Lankinen L. et al. Associations betweenhuman aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass and function // Circulation. – 1998. – Vol. 97. – P. 569-575.
Muller J. Regulation of aldosterone biosynthesis: physiological and clinical aspects. Monographs on Endocrinology. – 2nd ed. – N.Y.: Springer-Verlag, 1988. – Р. 29.
Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF et al. Heart Failure with Preserved, Borderline, and Reduced Ejection Fraction. Journal of the American College of Cardiology. 2017;70(20):2476–86. DOI: 10.1016/j.jacc.2017.08.074.
Tsao CW, Lyass A, Enserro D, Larson MG, Ho JE, Kizer JR et al. Temporal Trends in the Incidence of and Mortality Associated with Heart Failure with Preserved and Reduced Ejection Fraction. JACC: Heart Failure. 2018;6(8):678–85.
Weber K.T., Brilla C.G. Myocardial fibrosis and the renin-angiotensin-aldosterone system // J. Cardovasc. Pharmacology. – 1992. – Vol. 20. – P. 48-54.
License
Copyright (c) 2023 Mrfuzayl B. Sayfullaev, Abdigaffar G. Gadaev, Rustam I. Turakulov, Oybek Z. Abdukholikov
This work is licensed under a Creative Commons Attribution 4.0 International License.
The content published on the International Scientific and Current Research Conferences platform, including conference papers, abstracts, and presentations, is made available under an open-access model. Users are free to access, share, and distribute this content, provided that proper attribution is given to the original authors and the source.
